This article contains content that is written like an advertisement .(May 2019) |
Alvin J. Siteman Cancer Center | |
---|---|
Geography | |
Location | St. Louis, Missouri, United States |
Organization | |
Type | Specialist |
Affiliated university | Barnes-Jewish Hospital, Washington University School of Medicine |
Services | |
Speciality | Cancer |
Public transit access | MetroBus Red Blue At Central West End station |
History | |
Opened | 1999 |
Links | |
Website | www |
Lists | Hospitals in Missouri |
The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is a cancer treatment, research and education institution with six locations in the St. Louis area. Siteman is the only cancer center in Missouri and within 240 miles of St. Louis to be designated a Comprehensive Cancer Center by the National Cancer Institute (NCI). [1] Siteman is also the only area member of the National Comprehensive Cancer Network, [2] a nonprofit alliance of 32 cancer centers dedicated to improving the quality and effectiveness of cancer care. [3]
Siteman treats more than 75,000 individual patients, including 12,000 newly diagnosed patients, every year. [4]
Siteman's main facility is at Washington University Medical Center in St. Louis’ Central West End neighborhood. In 2021, work began on a new main facility on the medical campus that is scheduled for completion in summer 2024. [5] Five other St. Louis-area sites offer specialized cancer care in suburban locations:
In 1999, Alvin J. and Ruth Siteman committed $35 million to the development of the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital. The commitment was the largest gift ever received by Barnes-Jewish and Washington University in support of cancer research, patient care and services, education and community outreach. [9]
Timothy Eberlein has been director of the center since its inception. [10] John DiPersio is deputy director. [11]
In 2001, the NCI designated Siteman as a Cancer Center, which signaled that the institution had demonstrated significant scope and quality in its cancer research programs. The designation came with $850,000 per year in federal research grants. [12] The NCI named Siteman a Comprehensive Cancer Center in 2005, recognizing its broad-based research, outreach and education activities, and awarded the center a five-year, $21 million support grant. [13] The NCI renewed the designation in 2010 and awarded another five-year grant, totaling $23 million. The grants fund programs and specialized services that promote multidisciplinary research, as well as shared scientific resources and seed awards that enable investigators to develop and pursue new research opportunities. [14]
Alvin J. Siteman announced in 2010 that he would donate $1 million annually to an endowment fund at the center to advance cancer prevention, diagnosis and treatment programs that might not receive federal funding. [15]
More than 350 Washington University research scientists and physicians provide inpatient and outpatient care at Siteman. [16] The center also offers patient and family support services, including discussion and education groups. [17]
In 2018, Siteman announced it would build a second proton therapy unit at its S. Lee Kling Proton Therapy Center. The first opened in late 2013. [18]
Scientists and physicians affiliated with Siteman hold more than $145 million in cancer research and related training grants. The results of basic laboratory research are rapidly incorporated into treatment advances. This process is enhanced by patient access to more than 500 therapeutic clinical studies, [19] including many collaborative efforts with other leading cancer centers throughout the country. [20]
In 2013, three scientists affiliated with Siteman, Washington University School of Medicine and the McDonnell Genome Institute were included on the Thomson Reuters list of “Hottest Scientific Researchers of 2012”: Richard K. Wilson, Elaine Mardis, and Li Ding. The list recognized the 21 most-cited researchers of 2012. Robert Fulton, a fourth scientist from Washington University School of Medicine and the McDonnell Genome Institute, also made the list. [21]
Researchers affiliated with Siteman and/or Washington University School of Medicine have pioneered important advances in cancer research, prevention, education and treatment. Highlights and ongoing studies include these projects:
2018 — Personalized brain cancer vaccines
2017 — CAR-T cell therapy and using Zika virus to fight brain cancer
2016 — Chemotherapy for brain tumors
2015 — Melanoma vaccine and urine test for kidney cancer
2014 — Breast cancer vaccine and cancer goggles
2013 — Endometrial cancer and leukemia
2012 — Leukemia, breast cancer research and cancer prevention
2011 — Blood-related cancers
2010 — Pediatric cancers
2008 — Genetic sequencing
2007 — Nanotechnology and radiation therapy
2006 — Photoacoustic imaging
2003 — Breast cancer
2001 — Imaging and the immune system's role in controlling cancer
1998 — Biopsies
1994 — Genetic screening test for thyroid cancer
1979 — Bone marrow transplants
Mid-1970s — Imaging
1954 — Growth factors and cancer
1946 — Radiocarbon in cancer research
1941 — Cyclotron
1933 — Lung cancer surgery and the disease's link to smoking
Siteman and Washington University School of Medicine are actively engaged in many projects to prevent cancer in the St. Louis region and across the United States. These efforts include:
In addition to treatment and research programs, Siteman is involved with community outreach, education and screening. Efforts include:
In 2017, Siteman Cancer Center launched the Siteman Cancer Network, an affiliation with regional medical centers that is aimed at improving the health of individuals and communities through cancer research, treatment and prevention. Network members are Boone Hospital Center's Stewart Cancer Center in Columbia, Missouri, [69] Phelps Health's Delbert Day Cancer Institute in Rolla, Missouri, [70] Alton Memorial Hospital in Alton, Illinois [71] and Southern Illinois Healthcare in Carbondale, Illinois. [72]
Gene therapy is a medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other causes. Over 100 types of cancers affect humans.
This is a list of terms related to oncology. The original source for this list was the US National Cancer Institute's public domain Dictionary of Cancer Terms.
Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo, New York. Founded by surgeon Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short. The center, which conducts clinical research on cancer as well as the development new drugs, provides advanced treatment for all forms of adult and pediatric cancer, and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is as of 2019, the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. These branches use three different types of treatment methods: gene overexpression, gene knockout, and suicide gene delivery. Gene overexpression adds genetic sequences that compensate for low to zero levels of needed gene expression. Gene knockout uses RNA methods to silence or reduce expression of disease-causing genes. Suicide gene delivery introduces genetic sequences that induce an apoptotic response in cells, usually to kill cancerous growths. In a slightly different context, virotherapy can also refer more broadly to the use of viruses to treat certain medical conditions by killing pathogens.
The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.
Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.
The International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers. The ICGC was launched in 2008 to coordinate large-scale cancer genome studies in tumours from 50 cancer types and/or subtypes that are of main importance across the globe.
Lloyd John Old was one of the founders and standard-bearers of the field of cancer immunology. When Old began his career in 1958, tumor immunology was in its infancy. Today, cancer immunotherapies are emerging as a significant advance in cancer therapy.
Timothy J. Ley is an American hematologist and cancer biologist. He is the Lewis T. and Rosalind B. Apple Professor of Oncology in the department of medicine, and is chief of the section of stem cell biology in the division of oncology at Washington University in St. Louis. He is a member of the Alvin J. Siteman Cancer Center.
Racotumomab is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by ReComBio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
Cancer symptoms are changes in the body caused by the presence of cancer. They are usually caused by the effect of a cancer on the part of the body where it is growing, although the disease can cause more general symptoms such as weight loss or tiredness. There are more than 100 different types of cancer with a wide range of signs and symptoms which can manifest in different ways.
A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.
Childhood cancer is cancer in a child. About 80% of childhood cancer cases in high-income countries can be successfully treated via modern medical treatments and optimal patient care. However, only about 10% of children diagnosed with cancer reside in high-income countries where the necessary treatments and care is available. Childhood cancer represents only about 1% of all types of cancers diagnosed in children and adults, It is often more complex than adult cancers with unique biological characteristics and research and treatment is yet very challenging and limited. For this reason, childhood cancer is often ignored in control planning, contributing to the burden of missed opportunities for its diagnoses and management in countries that are low- and mid-income.
University of Virginia Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center affiliated with the University of Virginia School of Medicine and the UVA Health System.
David Hillel Gutmann is an American neurologist-neuroscientist. He teaches at Washington University in St. Louis, where he is the Donald O. Schnuck Family Professor, and Director of the Washington University Neurofibromatosis Center. He is an international expert in Neurofibromatosis, pioneering the use of preclinical models to understand brain tumors and neurodevelopmental delays in children with NF1.
Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).
David Terry Curiel is an American cancer biologist. He is a professor of Radiation Oncology at Washington University School of Medicine and Director of the Biologic Therapeutics Center. In 1995, Curiel led a research team who were the first to develop a vaccine based on messenger RNA. Although they published proof of concept, he could not continue testing due to a lack of funding. In 2021, Curiel developed a vaccine that targets the SARS-CoV-2 virus through the nose.
Rebecca Aft is an American surgical oncologist and breast cancer researcher. Holds the inaugural title of Moley Professor of Endocrine and Oncologic Surgery at Washington University School of Medicine in St. Louis. Aft studies the mechanisms of breast cancer metastasis and explores potential targets for treatment. Her work has identified the anti-metastatic effects of bisphosphonates in patients with breast cancer.